GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.

combien coûte du viagra
cialis vente libre en suisse
viagra est-il en vente libre en france
combien de temps le viagra agit
avis site vente cialis
viagra france pas cher
acheter viagra sans ordonnance en france

GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in gynecological cancers.

The company develops low-fucose EMABling® antibodies with increased tumor cell killing properties through the activation of immune system cells.